Kyocera Corporation (President: Hideo Tanimoto, hereafter "Kyocera") today announced that it has entered a license and collaboration agreement with Sydney, Australia-based Regeneus Ltd. (CEO: Leo Lee, hereafter "Regeneus") for exclusive rights in Japan to develop, produce, and commercialize Regeneus's unique cell-preparation*1 technology as a regenerative medical product for treating patients with knee osteoarthritis.
The technology licensed from Regeneus enables allogeneic mesenchymal stem cells*2 to be formulated into a cell preparation that can be administered to patients. Regeneus has completed an early clinical test in Australia for patients suffering from knee osteoarthritis, with promising results.
An estimated 25 million people in Japan exhibit osteoarthritic conditions in the knee, and approximately 8 million are fully symptomatic.*3 About 1.4 million in total are currently receiving treatment for arthrosis, including knee osteoarthritis, and the number increases yearly.*4 Kyocera aims to develop and commercialize the cell-preparation technology as a new product for treating these patients.
Kyocera is committed to developing new technologies and products that contribute to human health and well-being. The company is currently expanding its medical and healthcare R&D activities, which include orthopedic joint replacement systems and dental implants developed through its proprietary materials and surface-processing technologies, as well as regenerative medicine and presymptomatic treatments.
Overview of Regeneus
*1 Cell preparation involves regenerative medical techniques to create therapies by administering cells with secretions containing growth factors
*2 Allogeneic mesenchymal stem cells, which exist in fat, bone marrow, umbilical cords, and synovial membranes, are provided by donors other than the patients, and are capable of differentiating into bone, cartilage or muscle
*3 Yoshimura N, et al: Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27: 620―628,2009
*4 Patient Survey 2017-available in Japanese only-reported by Director-General for Statistics, Information Policy and Policy Evaluation, Ministry of Health, Labour and Welfare
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.
The technology licensed from Regeneus enables allogeneic mesenchymal stem cells*2 to be formulated into a cell preparation that can be administered to patients. Regeneus has completed an early clinical test in Australia for patients suffering from knee osteoarthritis, with promising results.
An estimated 25 million people in Japan exhibit osteoarthritic conditions in the knee, and approximately 8 million are fully symptomatic.*3 About 1.4 million in total are currently receiving treatment for arthrosis, including knee osteoarthritis, and the number increases yearly.*4 Kyocera aims to develop and commercialize the cell-preparation technology as a new product for treating these patients.
Kyocera is committed to developing new technologies and products that contribute to human health and well-being. The company is currently expanding its medical and healthcare R&D activities, which include orthopedic joint replacement systems and dental implants developed through its proprietary materials and surface-processing technologies, as well as regenerative medicine and presymptomatic treatments.
Overview of Regeneus
| Company name | Regeneus Ltd. |
|---|---|
| Location | Sydney, Australia |
| Established | 2007 |
| CEO | Leo Lee |
| Employees | 20 |
| Outline of business | In the field of orthopedics and treatment to aching pains, Regeneus is conducting cell -preparation research and development by utilizing platform technology uniquely developed from human mesenchymal stem cells. |
Company name
Regeneus Ltd.
Location
Sydney, Australia
Established
2007
CEO
Leo Lee
Employees
20
Outline of business
In the field of orthopedics and treatment to aching pains, Regeneus is conducting cell -preparation research and development by utilizing platform technology uniquely developed from human mesenchymal stem cells.
*1 Cell preparation involves regenerative medical techniques to create therapies by administering cells with secretions containing growth factors
*2 Allogeneic mesenchymal stem cells, which exist in fat, bone marrow, umbilical cords, and synovial membranes, are provided by donors other than the patients, and are capable of differentiating into bone, cartilage or muscle
*3 Yoshimura N, et al: Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27: 620―628,2009
*4 Patient Survey 2017-available in Japanese only-reported by Director-General for Statistics, Information Policy and Policy Evaluation, Ministry of Health, Labour and Welfare
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.
